Search

Displaying results 2951 - 2960 of 10000 in total
  1. Drug

    Otamixaban

    go.drugbank.com/drugs/DB06635
    Investigational

    Otamixaban is a novel direct Factor Xa (FXa) inhibitor. It is currently being developed by the French pharmaceutical company Sanofi-Aventis as a treatment for acute coronary syndrome.

    Categories: Factor Xa Inhibitors
  2. Drug

    JSM 6427

    go.drugbank.com/drugs/DB06139
    Investigational

    It has been biologically validated for therapeutic use in the prevention and treatment of wet AMD, the leading cause of blindness in people over the age of 55.

  3. Drug

    Cynodon dactylon pollen

    go.drugbank.com/drugs/DB10351
    Approved

    Cynodon dactylon pollen, also known as bermuda grass pollen, is a standardized grass pollen extracts used for the diagnosis and treatment of allergic disease to grass pollen. … Diagnostic allergenic extracts are primarily indicated for establishing clinical relevance of specific allergens to which the patient has been exposed and the degree of sensitivity the patient has toward

    Products: Center-AL - Cynodon Dactylon Pollen
  4. Drug

    Vinpocetine

    go.drugbank.com/drugs/DB12131
    Investigational

    Vinpocetine has been investigated for the treatment of Epilepsy.

    Categories: Compounds used in a research, industrial, or household setting, Psychostimulants, Agents Used for ADHD and Nootropics
  5. Drug

    XEN-D0101

    go.drugbank.com/drugs/DB06020
    Experimental

    XEN-D0101 is an investigational drug developed by Xention Inc. for the treatment of Atrial Fibrillation. XEN-D0101 works by being a selective antagonist of the voltage-gated potassium channel Kv1.5.

  6. Drug

    Vusolimogene oderparepvec

    go.drugbank.com/drugs/DB23008
    ApprovedInvestigational

    on a PD-1-blocking antibody-based regimen. … [L64061] It is administered by direct injection into superficial, deep, or visceral tumors.

  7. Drug

    Tozorakimab

    go.drugbank.com/drugs/DB16473
    Investigational

    history of exacerbations), and NCT06040086 (recruiting; symptomatic COPD with a history of exacerbations). … NCT04170543 (completed with results; diabetic kidney disease), NCT05624450 (recruiting; viral lung infection requiring supplemental oxygen), NCT05742802 (recruiting; long-term study in COPD patients with a

    Categories: Experimental Unapproved Treatments for COVID-19
  8. Drug

    L-tartaric acid

    go.drugbank.com/drugs/DB09459
    Approved

    , and is a dihydroxyl derivative of succinic acid. … Tartaric acid is a white crystalline organic acid that occurs naturally in many plants, most notably in grapes.Tartaric is an alpha-hydroxy-carboxylic acid, is diprotic and aldaric in acid characteristics

    Synonyms: (+)-L-tartaric acid, L-threaric acidMixtures: Unik Zoru Pwr
  9. Drug

    rGLP-1

    go.drugbank.com/drugs/DB05433
    Experimental

    rGLP-1 is a continuous infusion of glucagon-like peptide 1, or GLP-1, targeted for the treatment of congestive heart failure (CHF) in patients ineligible for transplant. … GLP-1 is a naturally occurring hormone produced in the intestines in response to food intake.

  10. Drug

    Idraparinux

    go.drugbank.com/drugs/DB06406
    Investigational

    Idraparinux, a synthetic pentasaccharide is an antithrombin-dependent inhibitor of activated factor X. It was developed for the treatment and prevention of thromboembolic events. … As a result, Sanofi stopped the development of the drug.

    Categories: Factor Xa Inhibitors